Ng D T, Francis I C, Schumacher R S, Alexander S L
Sydney Eye Hospital, Sydney, New South Wales, Australia.
J Cataract Refract Surg. 2001 Sep;27(9):1437-9. doi: 10.1016/s0886-3350(01)00796-9.
To describe the experience of 1 surgeon's first 115 cases using the Allergan Unfolder intraocular lens (IOL) injection system.
Free-standing day-surgery center, Chatswood, Australia.
After standard phacoemulsification, an SI-40NB IOL (Allergan) was implanted using the Unfolder. Data on complications and the success of implantation were collected prospectively.
Ninety-four percent of patients achieved a 1 month visual acuity of 6/6 or better. Of the 13 cases with a potential complication related to the Unfolder, all achieved a visual acuity of 6/6 or better. No complication affected the eye adversely or reduced visual acuity significantly.
Implantation of SI-40NB IOLs with the Unfolder led to no serious complications and gave satisfactory visual results.
描述一位外科医生使用艾尔建（Allergan）展开式人工晶状体（IOL）注射系统进行的最初115例手术的经验。
澳大利亚查茨伍德独立日间手术中心。
在标准超声乳化术后，使用展开式系统植入SI-40NB型人工晶状体（艾尔建）。前瞻性收集有关并发症及植入成功率的数据。
94%的患者术后1个月视力达到6/6或更佳。在13例与展开式系统相关的潜在并发症病例中，所有患者视力均达到6/6或更佳。没有并发症对眼睛造成不良影响或显著降低视力。
使用展开式系统植入SI-40NB型人工晶状体未导致严重并发症，视觉效果令人满意。
